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ABSTRACT
Healthcare costs are rising due to an increase in chronic diseases, including chronic myeloid leu-
kemia (CML) due to improved survival. In CML care, patient adherence and physician adherence
are key elements. We assessed the potential health gain and cost savings when both are
improved, using a decision analytic model that integrated various sources of evidence. The cur-
rent situation was compared to a theoretical situation in which either patient or physician
adherence is improved, in terms of costs and quality-adjusted life years (QALYs). Current patient
adherence rate is 74%, improvement to 100% resulted in 0.1031 QALYs gained and a saving of
e17,509 per patient over a 25-year period. Improving physician adherence from 72% to 100%,
resulted in 0.0380 QALYs and e7606. Enhancement of either adherence results in substantial
health gain and cost savings. Regarding the rising healthcare costs, new strategies should focus
on improving adherence to keep healthcare affordable in the future.
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Introduction
The advent of tyrosine kinase inhibitors (TKIs) has
drastically improved the treatment of patients with
chronic myeloid leukemia (CML). The 10-year overall
survival in newly diagnosed CML patients in chronic
phase (CML-CP) has improved from historically less
than 20% to a current 83.3% when treated with the
first approved TKI imatinib [1,2]. As a consequence,
the prevalence of CML is steadily rising worldwide and
is estimated to reach a plateau at approximately 35
times its incidence by 2050, which would lead to a
total of more than 180,000 patients in the United
States [3]. The increasing prevalence will result in an
increase in costs and health care utilization.
In the current CML care, two elements are of major
importance, with the first being physicians’ adherence
to the international guidelines of the National
Comprehensive Cancer Network (NCCN) and European
Leukemia Network (ELN) [4,5]. Multiple studies, how-
ever, have shown that guideline adherence in CML
care is often suboptimal [6–8].
Preliminary results from a national population-
based study showed inadequate monitoring in the
first year of TKI treatment in 28% of the newly diag-
nosed CML-CP patients in the Netherlands, whereas
patients who received optimal molecular monitoring
had a significant higher overall survival [9]. This is con-
sistent with other studies, showing that 54% of the
patients were monitored less than 3 times a year and
had a significantly higher risk of progression to
advanced phase disease and death [10].
Second, adherence by patients is crucial and a daily
challenge in CML management. In the literature, mean
adherence rates ranged from 79% to 98% and only
small percentages of patients were perfectly adherent
whilst many were suboptimal adherent [11–13].
Suboptimal adherence, defined as an intake of less
than 90% of the TKIs, is strongly correlated with lower
rates of achieving therapeutic goals such as complete
cytogenetic response and major and complete
molecular responses (MMR and CMR) in patients
treated with imatinib [13–15]. This is associated with a
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higher rate of progression [13,16]. Main reasons
described for low adherence are side effects and for-
getfulness, resulting in intentional and nonintentional
nonadherence, respectively [17–21]. It is clear that bet-
ter adherence by both the physician and the patient is
associated with better outcomes. However, the actual
quantitative impact of improving both physician and
patient adherence on CML patients as well as on
health care costs has not been established yet. Hence,
the aim of this study was to assess the potential
health benefit and costs of (1) improving patient
adherence to TKIs and (2) improving guideline adher-
ence by physicians.
Methods
Population
The current assessment included patients in the
Netherlands diagnosed in CML-CP. This comprises
approximately 95% of the newly diagnosed patients
with CML, resulting in around 160 new patients per
year in the Netherlands [22].
Model structure
We developed a state transition model to assess the
potential value of improving both patient adherence
to TKIs and physician adherence to guidelines.
A representation of the model structure with different
steps is presented in Figure 1. In the model, costs and
effects are estimated for two strategies: the current
situation and a situation in which either patient adher-
ence or physician adherence is improved. The poten-
tial of improvement of the specific adherence is
represented by the difference between the improved
and the current situation. In both strategies, patients
start in CP. Since adherence rate influences the treat-
ment response, in the model adherence is related to
the probability of reaching MMR. Subsequently,
whether a patient achieves MMR determines the prob-
ability of disease progression to accelerated phase or
blast crisis (BC), which results in a higher mortality
rate. However, the achievement of MMR can also be
followed by a CMR. When CMR is maintained for at
least 1 year, in some of the patients TKI treatment
could be discontinued; called treatment-free remission.
For both patient adherence and physician adherence,
the same model structure was used, though with dif-
ferent probabilities. To every state, a certain quality of
life (QOL) (utility) value and costs were assigned.
Utilities
Health-related QoL was the outcome measure in this
model and is expressed as a utility value on a scale
from 0 (representing death) to 1 (representing perfect
health). The use of utility scores allows the calculation
Figure 1. Structure of the model and its steps. CP: chronic phase; AP: accelerated phase; BC: blast crisis; CMR: complete molecular
response; MMRþ: major molecular response (on 18 months in model for patient adherence, and 12 months in model for guide-
line adherence); MMR: no major molecular response (on 18 months in model for patient adherence, and 12 months in model
for guideline adherence).
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of quality-adjusted life years (QALYs) [23]. Utility values
for patients in CP and in disease progression (AP and
BC) are described: 0.854 and 0.595, respectively [24].
Costs
Two types of costs were included in the model: costs
of treatment and costs of hospital visits. The volumes
of use differ in the several phases of CML. Cost prices
for polymerase chain reaction (PCR), TKIs, stem cell
transplantation (SCT), hematologist visits and hospital
days are shown in Appendix Table 4. Since the price
of generic imatinib is negotiable, sensitivity analyses
were performed in which the price of imatinib varied.
The assumptions made are described in Appendix A.
Probabilities: patient adherence
Adherence and outcome. Patient adherence to TKIs
was defined as an intake of more than 90% of the pre-
scribed medication. The probability that a patient is
adherent to TKIs is 73.6% [16]. Adherence influences
the chance of reaching MMR at 18 months: the prob-
ability is 57.8% in adherent patients versus 8.7% in
nonadherent patients. This association is only reported
for imatinib and no data are available for adherence
to TKIs used in the second-line, such as dasatinib and
nilotinib, in relation to treatment outcomes. Therefore,
we assumed the same difference as for imatinib in the
probability of reaching MMR between adherent and
nonadherent patients.
Progression into accelerated phase. The probabil-
ity of progression from CP to the next phase in the
disease, i.e. accelerated phase (AP), is reported to be
0.9% in patients who have reached MMR at 18
months. When MMR at 18 months is not achieved,
this probability increases to 9.9% [25]. In case of pro-
gression, it is likely to happen within the first 3 years
after the 18-month response period. Therefore, we
assumed a linear progression rate in these first
3 years.
Progression into BC. In case of progression, we
assumed that patients went in AP before going into
BC. This probability is 75% [26] and we assumed an
average of 12 months for progression to take place.
BC has a high mortality: at 3 years after diagnosis of
BC, 76% of the patients has died [27]. The median sur-
vival after BC diagnosis is 9 months. For the model,
we assumed an average survival of 1 year (Appendix
Table 1). The other part of BC patients comprises
long-time survivors which were assumed to have a
survival equal to that of the general population
(Appendix Table 2) [28].
Achieving CMR. The probability that patients will
reach CMR is also influenced by patients’ adherence.
Adherent patients have a 6-year probability of 43.8%
to achieve CMR, whereas no nonadherent patients will
reach CMR [16]. We conservatively assumed that after
6 years the chance to achieve CMR is zero. The proba-
bilities to achieve CMR per year are shown in
Appendix Table 1. Patients that stay in CP, AP or reach
CMR were assumed to have a survival which is equal
to that of the general population (Appendix Table
2) [28].
Probabilities: physician adherence
Physician adherence was defined as adherence to the
ELN guidelines [4]. In these guidelines, a series of spe-
cific time-dependent molecular treatment response cri-
teria are established; for the first 3 years of treatment
they are defined as a BCR-ABL1 of 10%, 1%, and
0.1% (MMR) at 3, 6, and 12 months, respectively.
When these response criteria are not met and patient
adherence is optimal, the TKI received as current treat-
ment should be substituted with an alternative TKI. In
the Netherlands, a rate of patients receiving adequate
molecular monitoring of 72% was observed [9].
Adherence and outcome. To determine the value
of improving physician adherence, we compared a
nonadherent situation versus an adherent situation.
For the first and nonadherent situation, we used a
data from the IRIS trial [25], in which patients used
only imatinib and could not switch to second-line TKI
if they failed the targets. In this study, 40% of the
patients reached MMR at 12 months [29], which we
assumed to be an indicator for the probability of
reaching MMR in a nonadherent situation.
For the second and adherent situation, we used
data from the TIDEL-II study [30]. When treatment out-
comes were not reached, patients switched to a
second-line TKI. At 12 months, 64% reached MMR. The
difference in MMR could be partially due to the higher
dose of imatinib (600mg vs. 400mg in IRIS study) and
not only to the possibility of switching TKIs. This could
result in an overestimation of the difference in MMR
between the adherent and nonadherent situation.
Therefore, we performed a sensitivity analysis in which
we used data from the TIDEL-I study for the nonadher-
ent situation. In this study patients received 600mg of
imatinib and could not switch to a second line TKI in
case of low response. MMR at 12 months was reached
by 47%. However, in this study patients did get a
dose escalation (to 800mg) in case of low response
and this could, therefore, result in an underestimation
of the effect of adherence.
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Progression. The effect of achieving MMR on the
probability of disease progression at 12 months is
similar to that at 18 months [25]. Therefore, we used
the same probabilities as we used for patient adher-
ence, based on achievement of MMR at 18 months
instead of 12 months.
Achieving CMR. When only imatinib was used, i.e.
the nonadherent situation (IRIS study), 30% of the
patients reached CMR after 5 years [16]. In the TIDEL-II
study, i.e. the adherent situation, the 5-year probability
of CMR was 50%. Hence, we assumed a difference in
probability of achieving CMR of 20% in patients who
underwent adequate versus inadequate monitoring.
For the sensitivity analysis, where 47% MMR of the
TIDEL-I study as non-adherent situation was used
instead of the 40% from the IRIS study, we also
included a lower difference in the probability of
achieving CMR (14% instead of 20%). Since the CMR
rate was not shown in the TIDEL-I study, this reduction
in CMR was in proportion to the difference in MMR
between the IRIS and TIDEL-I study.
An overview of the probabilities is shown in
Appendix Table 3.
Analysis
Using the decision analytic model, we compared the
current situation with a theoretical situation in which
either patient adherence or physician adherence was
perfect (100%). Additionally, we calculated the value
of each percentage point increase in adherence. The
outcomes costs and effects were defined in euros and
QALYs, respectively. They were determined both per
patient and over a total of 160 new patients per year.
Since no costs were assigned for a new strategy in the
theoretical situation, the differences in costs represent
the room for investment in a new strategy. That is,
the costs that could be made in order to improve
adherence without making CML care more expensive.
Future costs and effects were discounted at 4%, and
1.5% annually, following the Dutch guideline for eco-
nomic evaluation [31]. Sensitivity analyses with differ-
ent prices of imatinib were performed for both patient
adherence and physician adherence. A sensitivity ana-
lysis with a different percentage of patients reaching
MMR (and a difference in probability of reaching CMR)
in the non-adherent situation was performed for phys-
ician adherence.
Results
Patient adherence
In current clinical practice, 73.6% of the patients are
adherent [16]. Over a period of 25 years, in the current
situation patients yielded on average 13.83 QALYs and
the mean costs per patient were e422,066. Compared
to this, perfect adherence resulted in a gain of 0.1031
QALYs and a saving of e17,509 per patient (Table 1).
Over 25 years, for each yearly cohort of patients,
improving adherence could result in a total cost sav-
ing of approximately e2.8 million and a gain of 16.5
QALYs maximum.
Each percentage point increase in patient adher-
ence resulted in 0.0039 QALYs gained and a saving of
e666 per patient. Over 25 years, for each yearly cohort,
this resulted in a total cost reduction of e106,560 and
gain of 0.624 QALY per percentage point improve-
ment in adherence (Table 2). When the price of imati-
nib is reduced by 90%, in a situation with 100%
patient adherence, sensitivity analyses showed that
potential cost saving was approximately halved: e9037
(Table 5).
Physician adherence
The current physician adherence to guidelines regard-
ing adequate molecular monitoring in the Netherlands
is 72% [9]. The current situation yields 13.95 QALY and
mean costs of e452,578 per patient over a period of
25 years. When comparing the situation where adher-
ence is 100%, 0.0380 QALYs were gained and e7606
was saved per patient. Over the time period of 25
years and with a total of 160 patients per year this
would result in a potential cost saving of e1.2 million
and a gain of 6.08 QALYs (Table 3).
Each percentage point increase in adherence
resulted in 0.0014 QALYs gained and a saving of e272
per patient. The total potential cost reduction, for
each yearly cohort, was e43,520 (Table 4). In the case
of a 90% price reduction of imatinib, in a situation
with 100% adherence, sensitivity analyses showed a
Table 1. Room for improvement in patient adherence over 25 years.
Adherence QALY Costs (e)
Current situation 73.6% 13.8331 422,066
Full adherence 100.0% 13.9361 404,557
Difference 26.4% þ0.1031 17,509
Total difference per yearly cohort of 160 patients n/a þ16.496 2,801,440
Per patient.
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potential cost saving of e607 per patient (Table 5).
These results were based on the difference in MMR
rate at 12 months between the IRIS study (as nonad-
herent situation, 40% MMR) and the TIDEL-II study (as
adherent situation, 64% MMR). Sensitivity analyses
were performed with the results of the TIDEL-I study
representing the nonadherent situation (47% MMR),
resulting a gain in QALY of 0.0223 and saving e5323
per patient with 100% adherence.
Discussion
For patient adherence, the total room for improve-
ment in costs is approximately e2.8 million for each
yearly cohort of 160 patients over a time period of 25
years with a potential gain of 16.496 QALYs. For
guideline adherence, the potential improvement in
costs was e1.2 million with a potential gain of 6.08
QALYs. Given the reported adherence rates in inter-
national studies of patients to TKIs, with only 20–53%
of the patients fully (i.e. 100%) adherent and most
patients being suboptimal adherent [11], current ther-
apy may not be used to its full potential. With the
estimated gain in costs and QALYs per percentage
point increase in adherence, one could argue that
exploring strategies to improve adherence to current
therapies and thereby enhancing their potentials
should be of main focus.
In the model, several assumptions had to be made.
First, the difference between adherent and nonadher-
ent patients in treatment response has only been
studied in patients using imatinib [16]. This difference
in response between adherent and nonadherent
patients could be different for second-generation TKIs.
It is difficult to predict whether this could have
resulted in an overestimation or underestimation of
the potential value of increasing adherence. Secondly,
since physician adherence has never been directly
compared to physician nonadherence there are no
other data available than of indirect comparisons.
Table 2. Gain for each percentage point increase in patient adherence over
25 years.
Adherence QALY Costs (e)
Current situation 73.7% 13.8331 422,066
Percentage point increase in adherence 74.7% 13.8370 421,400
Difference 1.0% þ0.0039 666
Total difference per yearly cohort of 160 patients n/a þ0.624 106,560
Per patient.
Table 3. Room for improvement in physician adherence over 25 years.
Adherence QALY Costs (e)
Current situation 72.0% 13.9476 452,578
Full adherence 100.0% 13.9856 444,972
Difference 28.0% þ0.0380 7606
Total difference per yearly cohort of 160 patients n/a þ6.08 1,217,120
Per patient.
Table 4. Gain for each percentage point increase in physician adherence over
25 years.
Adherence QALY Costs (e)
Current situation 72.0% 13.9476 452,578
Percentage point increase in adherence 73.0% 13.9490 452,307
Difference 1.0% þ0.0014 272
Total difference per yearly cohort of 160 patients n/a þ0.22 43,520
Gain is the same for each percentage point increase.Per patient.
Table 5. Sensitivity analysis.
Price of imatinib (Price per year)
Potential cost savings per patient with full patient
adherence (e)
Potential cost savings per patient with full
physician adherence (e)
2015 price imatinib (e32,075) 17,509 7606
25% lower price imatinib (e24,056) 15,156 5662
50% lower price imatinib (e16,038) 12,802 3718
75% lower price imatinib (e8,019) 10,449 1774
90% lower price imatinib (e3208) 9037 607
99% lower price imatinib (e321) 8189 þ93
The results presented in the Table are over the time period of 25 years.
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Therefore, we compared data of the IRIS trial [32] with
data of TIDEL-II trial [30]. In this indirect comparison,
other factors such as variety in population could play
a role and may have resulted in an under- or overesti-
mation of the potential value of improving physician
adherence. The higher dose of imatinib used in the
TIDEL-II trial may have resulted in an overestimation
of the potential value. Hence, we performed sensitivity
analyses with results of the TIDEL-I study instead of
the IRIS trial, resulting in a lower potential value of
improving physician adherence and a potential under-
estimation. Additionally, at the time of developing the
model preliminary results showed a rate of suboptimal
monitoring 2% higher than the final published study
[22], which could lead to an overestimation of the
potential. Third, we assumed the possibility of discon-
tinuing TKIs in patients in CMR. Yet, currently, a more
often used indicator is the deep molecular response
(DMR). However, there are no data available on the
influence of physician and patient adherence on the
probability of achieving DMR. DMR is a less strict def-
inition compared to CMR; therefore, patients are more
likely to achieve DMR than CMR resulting in a possible
underestimation of the potential. Last, although side
effects are often reported by patients as a reason for
nonadherence in general, there are no data available
on the direct influence of side effects of TKIs on the
utility (i.e. QALY) of patients. Therefore, the model
does not cover the negative influence of possible side
effects on QALYs. By increasing TKI adherence patients
could experience more side effects and have a
decrease in QALY gain. Nevertheless, the decrease in
side effects when TKI therapy can be discontinued has
not been included in the model either. Since TKI
adherence is crucial in achieving treatment goals and
subsequently eligibility for treatment discontinuation,
the actual health benefits of improving adherence
could be higher.
A possible solution may come from e-Health tech-
nology. With forgetfulness being the main reason of
unintentional nonadherence, investments in e-Health
interventions that, for example, remind patients to
take their medication, could provide a straightfor-
ward solution.
Since side effects are the main cause of intentional
nonadherence, adequate management on reported
adverse events is a necessity. Strategies to educate
patients on their treatment and possible adverse
events and help them manage these using, for
instance, e-Health technologies would be worth
exploring. By using the assessments as performed in
this study one can determine the room for investment
by computing the costs savings that come with
improved adherence. The number of QALYs gained
per patient may not seem that high, however, this
was calculated for our whole annual cohort of CML
patients, whereas only the nonadherent patients will
benefit in QALYs.
Improving physician adherence can save costs and
gain QALYs as well. Reported reasons of nonadher-
ence include lack of familiarity, medical resource bar-
riers in implementation as well as high costs of TKI
medication and other patient resources [33]. Here too
technology can help to improve physician adherence
by providing educational programs to improve famil-
iarity and facilitate implementation of guidelines in
daily practice [33]. As for patient resources as barrier,
the high costs of TKIs will not decrease by developing
new ones but by using the ones with generic variants
available. Nevertheless, in the same study that
explored the reasons of nonadherence to CML guide-
lines by surveying hematologist-oncologists, additional
trainings or efforts to facilitate guideline adherence
were not considered important by physicians. This
calls for a culture change in CML management by
healthcare professionals.
At the time of writing, generic imatinib just became
available at a lower price than GleevecVR [Novartis,
Basel, Switzerland]. Sensitivity analyses were per-
formed with price reductions up to 90% for generic
imatinib and still costs were saved by improving either
patient or physician adherence. Except in case of a
99% reduction, where full physician adherence
costs money (e93 per patient) because of an increase
in TKI switches and hence use of next-line TKIs.
Developments in therapies will produce new and
patented medication. Which, despite a possible earlier
achievement of treatment goals, should demonstrate
an advantage in survival rate in order to be prescribed
instead of the cheaper generic alternative. This might
be quite the challenge since the most recent update
of the CML-IV study reported a 10-year relative sur-
vival probability of 92% and a 10-year CML-mortality
of 6% in patients receiving first-line imatinib [34]. With
the survival rates of CML-CP patients approaching the
survival rates of the general population the question
is raised how many patients one needs to treat in
order to attain an advantage in survival over the cur-
rent TKIs. Besides, even when current TKI therapy is
not molecularly monitored at all and subsequently no
adjustments are made in case of failure, 3-year pro-
gression-free survival was 83% [10]. The current study
did not make a direct comparison between the costs
savings and QALY gain between improved adherence,
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either patients’ or physicians’, and new generation
TKIs though. In future research, newer generation TKIs
should be evaluated through this model as soon as
data on probabilities are known. It should include the
sensitivity analyses for price reductions through gen-
eric alternatives as performed in the current study,
combined with the probabilities of sustained molecu-
lar remission and discontinuation of TKI treatment.
Furthermore, the scope of the model could be broad-
ened, including the probabilities of adverse events of
newer generation TKIs, which may be more serious
than with current therapies.
With the increasing prevalence of CML and other
chronic diseases, healthcare costs and utilization in
general are rapidly rising. In this light, the importance
of assessments as performed in this study is empha-
sized in order to determine whether investments in
improving adherence seem worthwhile and whether
they could be cost-effective. Furthermore, improving
adherence, both patients’ and physicians’, show great
potential in health-care cost reduction and gained
QALYs. Further research on development of interven-
tions improving adherence should be conducted. The
results of this study in combination with the current
literature demonstrate the gaps in the current care
that need to be addressed in order to be able to keep
providing the best care possible in the near future.
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